Health / WORLD

United Therapeutics completes first UThymoKidney xenotransplant in EXTEND trial

United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

United Therapeutics Corporation announced on 20 November 2026 that the first clinical xenotransplant has been completed in its EXTEND study evaluating the investigational UThymoKidney in patients with end-stage renal disease. The surgical procedure took place at NYU Langone Health, led by Robert Montgomery, chair of the Department of Surgery at NYU Grossman School of Medicine and director of the NYU Langone Transplant Institute. The company described EXTEND as the first clinical trial designed to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage kidney failure, and the second clinical trial in its manufactured xeno-organ pipeline.

The EXTEND study, registered as NCT07224763, is structured as a multicenter, open-label, combination Phase 1/2/3 clinical trial intended to support a future Biologics License Application with the U.S. Food and Drug Administration. Rather than separating safety, dose-finding and pivotal efficacy into distinct sequential trials, this phaseless design progresses through staged clinical gates. Eligible participants are patients with end-stage renal disease who are not eligible for conventional human kidney transplantation, or who are listed on an Organ Procurement and Transplantation Network waitlist but are statistically more likely to die or remain untransplanted within five years than to receive a human donor organ.

Unlike multi-gene-edited porcine organs tested in other clinical studies, the UThymoKidney is derived from a pig with a single genetic modification and incorporates porcine thymic tissue grafted beneath the kidney capsule. The single edit inactivates the porcine gene responsible for synthesising alpha-gal, a cell-surface sugar that triggers immediate hyperacute rejection when porcine tissue enters the human bloodstream. The co-transplanted porcine thymus tissue is intended to condition the recipient's immune system over time to recognise the organ as self, aiming to lower the likelihood of long-term rejection alongside required immunosuppressive therapy.

Under the protocol outlined by United Therapeutics, each participant who receives a UThymoKidney undergoes a 24-week post-transplant follow-up period during which all primary efficacy endpoints and safety assessments are evaluated. Following the 24-week window, recipients will remain under lifelong monitoring for graft function and potential zoonotic infections. Key efficacy measures at 24 weeks include participant survival rate, UThymoKidney survival rate, change in measured glomerular filtration rate, donor-specific hyporesponsiveness assessed by the Mixed Lymphocyte Reaction assay, and quality of life measured across four standardised instruments, alongside overall patient and graft survival times.

Safety oversight in the trial tracks the incidence of adverse events and serious adverse events, all-cause mortality, proteinuria, zoonotic infections and opportunistic infections associated with immunosuppression. The first six transplants are planned across two clinical centers, with a mandatory 12-week waiting interval between the first and second procedures. Once all six initial recipients have reached at least 12 weeks post-transplant, an Independent Data Monitoring Committee will review accumulated safety and efficacy data to determine whether the study should proceed. United Therapeutics plans to present those six-patient results to the FDA before adding centers or expanding enrolment.

EXTEND runs alongside two other xeno-organ programs at United Therapeutics. The EXPAND trial, registered as NCT06878560, is a multicenter open-label registration study evaluating the company's UKidney in patients with end-stage renal disease at NYU Langone Health and Northwestern Medicine. A third study, EXPRESS, is planned as an open-label trial of the investigational UHeart in advanced heart failure, beginning at a single site. Both UKidney and UHeart are derived from pigs carrying 10 genetic edits, comprising six added human genes to promote immunological compatibility and four knocked-out porcine genes to reduce rejection risk and moderate organ growth.

Company leadership and the surgical team framed the milestone as a disciplined step rather than proof of clinical efficacy. Jayme Locke, chief medical officer for xenotransplantation at United Therapeutics, noted that the launch reflects years of scientific, facility and regulatory work, while Leigh Peterson, executive vice president for product development and xenotransplantation, emphasised methodical progression with patient safety first. Montgomery pointed to the daily mortality among patients awaiting human kidneys and said the EXTEND protocol offers a rigorous test of whether thymokidney xenotransplantation can deliver measurable benefit for people with few remaining clinical options.

United Therapeutics cited national kidney disease figures to underscore the scale of the supply gap. According to data from the American Kidney Fund and the 2024 United States Renal Data System Annual Report referenced in the release, approximately 830,000 people in the United States live with kidney failure, more than 550,000 depend on dialysis and over 90,000 are on the kidney transplant waiting list, while only about 22,000 deceased-donor kidney transplants occurred in 2025. Three years after starting dialysis, only 12 percent of patients had been placed on the national waitlist and more than 40 percent had died without receiving a transplant.

The company stressed that UThymoKidney, UKidney and UHeart are all investigational products not approved in any jurisdiction for any indication. Completing the first transplant establishes procedural feasibility in the EXTEND study, but clinical durability, immunological tolerance, infection surveillance and regulatory acceptability will only become clear as the 12-week interval, the six-patient monitoring review and the 24-week endpoint evaluations unfold. Future clinical disclosures and FDA feedback will determine whether the single-edit thymokidney platform can scale into a larger pivotal cohort.

Data

Key figures

Key reported figures

Selected clinical trial design and US kidney failure figures reported in the United Therapeutics press release.

Initial EXTEND study cohort before FDA review
6 patients
2026-11-20 · Target
Post-transplant primary follow-up window in EXTEND
24 weeks
2026-11-20 · Observed
Approximate US patients with kidney failure
≈830,000 patients
2026-11-20 · Estimate
Approximate US deceased-donor kidney transplants in 2025
≈22,000 cases
2025 · Estimate
Share of US dialysis patients waitlisted after three years
12 percent
2024 · Observed
Methodology

Figures retain the source's stated period, population, scope and definitions. Estimates and targets are labeled by basis. No missing value is inferred.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United States · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredir.unither.com ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

Johnson & Johnson reports Phase 4 STAR trial gains for TREMFYA in axial psoriatic arthritis

Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.

Johnson & Johnson, Phase 4 STAR Study Results for TREMFYA in Axial Psoriatic Arthritis5 min read Data included
Health

Everest Medicines doses first patient in ASCEND Phase 2b trial of VIS-101 for wet AMD

Everest Medicines announced on 20 November 2026 that the first patient was treated in China in the 244-patient Phase 2b ASCEND trial comparing VIS-101 against 2 mg aflibercept in wet age-related macular degeneration, ahead of a planned 2027 global Phase 3 program.

Everest Medicines, First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD4 min read Data included